HNB
ARQT icon

Huntington National Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Huntington National Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.4K Sell
780
-33
-4% -$842 ﹤0.01% 1674
2025
Q4 		$23.6K Sell
813
-210
-21% -$5.38K ﹤0.01% 1520
2025
Q3 		$19.3K Buy
1,023
+49
+5% +$773 ﹤0.01% 1611
2025
Q2 		$13.7K Sell
974
-38
-4% -$533 ﹤0.01% 1698
2025
Q1 		$15.8K Buy
1,012
+7
+0.7% +$99 ﹤0.01% 1599
2024
Q4 		$14K Buy
1,005
+36
+4% +$394 ﹤0.01% 1650
2024
Q3 		$9.01K Sell
969
-133
-12% -$1.31K ﹤0.01% 1797
2024
Q2 		$10.2K Sell
1,102
-35
-3% -$317 ﹤0.01% 1685
2024
Q1 		$11.3K Buy
1,137
+10
+0.9% +$75 ﹤0.01% 1650
2023
Q4 		$3.64K Sell
1,127
-75
-6% -$204 ﹤0.01% 1966
2023
Q3 		$6.38K Buy
1,202
+14
+1% +$119 ﹤0.01% 1724
2023
Q2 		$11.3K Buy
1,188
+219
+23% +$2.43K ﹤0.01% 1535
2023
Q1 		$10.7K Sell
969
-22
-2% -$318 ﹤0.01% 1508
2022
Q4 		$14.7K Buy
+991
New +$17.3K ﹤0.01% 1379

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Huntington National Bank's ARQT Position: Q1 2026 in Review

Huntington National Bank reduced its Arcutis Biotherapeutics (ARQT) stake by 4.1% in Q1 2026, selling an estimated $842 and leaving 780 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

Huntington National Bank first reported a position in ARQT in Q4 2022 and has held it in 14 quarters since. The position peaked at $23.6K in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Huntington National Bank held 780 shares of Arcutis Biotherapeutics worth $18.4K as of Q1 2026.
  • Huntington National Bank sold 33 Arcutis Biotherapeutics shares in Q1 2026, an estimated $842.
  • Arcutis Biotherapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1674 holding.
  • Huntington National Bank first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 14 quarters since.
  • Huntington National Bank's Arcutis Biotherapeutics position peaked at $23.6K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.